Insilico Medicine ALS AI
Click to visit website
About
Insilico Medicine provides an AI-driven platform focused on drug discovery and personalized research for Amyotrophic Lateral Sclerosis (ALS). The platform employs deep generative models, reinforcement learning, and other modern machine learning techniques to facilitate novel target identification and the generation of novel molecular structures with desired properties. Founded in 2014, Insilico Medicine has partnered with numerous pharmaceutical and biotech companies, launching multiple R&D pipelines targeting difficult and previously undruggable diseases. The established platform, featuring tools such as PandaOmics, Chemistry42, and InClinico, accelerates the process of drug discovery for ALS by analyzing patient data to identify new therapeutic pathways and potential drug repurposing opportunities, ultimately aiming to enhance personalized medicine for ALS patients.
Platform
Task
Features
• reinforcement learning
• ai-driven drug discovery
• deep generative models
• target identification
• drug repurposing
• collaboration with research organizations
• innovative therapies development
• user-friendly interface for data analysis
Pricing Plans
Free
Free Plan• Access to basic features of PandaOmics
• Target identification tools
• Basic analytics capabilities
Average Rating: 0.0
Average Rating: 0.0
5 Stars:
0 Ratings
4 Stars:
0 Ratings
3 Stars:
0 Ratings
2 Stars:
0 Ratings
1 Star:
0 Ratings
User Ratings
No ratings available.
Sign In to Rate this Tool
Alternatives
BenevolentAI
AI platform for drug discovery using advanced data analytics and machine learning.
View Details
Denovo Sciences Platform
AI-powered platform for drug discovery using novel therapeutics and machine learning.
View Details
MindRank
AI-powered small molecule drug discovery platform accelerating drug development.
View DetailsFeatured Tools
Scalytics Connect
A federated AI framework that integrates decentralized data sources for AI development.
View Details